SCHEMBL5028690

SCHEMBL5028690

COc1ccc(CSC(C)=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.62
HDAC3 O15379 1/20 0.59
HDAC4 P56524 1/20 0.59
HDAC1 Q13547 1/20 0.59
HDAC7 Q8WUI4 1/20 0.59
HDAC2 Q92769 1/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC11 Q96DB2 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
HDAC9 Q9UKV0 1/20 0.59
HDAC5 Q9UQL6 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.50
HTT P42858 1/20 0.50
LDHA P00338 1/20 0.50
F2RL1 P55085 1/20 0.49
EPHX1 P07099 1/20 0.48
TAAR1 Q96RJ0 1/20 0.47
FFAR1 O14842 1/20 0.47
SAE1 Q9UBE0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25396130 0.90 NPC1 (0.60) IDO1HDAC3HDAC4HDAC1HDAC7
SCHEMBL8488722 0.85 IDO1 (0.62) IDO1SMN1; SMN2HTTLDHAF2RL1
SCHEMBL6571602 0.84 IDO1 (0.67) IDO1HDAC3HDAC4HDAC1HDAC7
SCHEMBL14611612 0.83 LMNA (0.52) IDO1HDAC3HDAC4HDAC1HDAC7
SCHEMBL10789554 0.83 IDO1 (0.61) IDO1SMN1; SMN2HTTLDHAF2RL1
SCHEMBL13905831 0.81 IDO1 (0.59) IDO1HDAC3HDAC4HDAC1HDAC7
SCHEMBL10823756 0.81 IDO1 (0.59) IDO1SMN1; SMN2HTTLDHAF2RL1
SCHEMBL8436880 0.81 IDO1 (0.59) IDO1HTTLDHAF2RL1EPHX1
SCHEMBL8938869 0.80 IDO1 (0.57) IDO1SMN1; SMN2HTTLDHAF2RL1
SCHEMBL8163509 0.80 CYP1A2 (0.64)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3953341-B1 NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI PI INDUSTRIES LTD (IN) 2023-07-26 EP claimed
US-20150232616-A1 HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS INTEZYNE TECHNOLOGIES, INC. 2015-08-20 US disclosed
US-8980326-B2 Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents INTEZYNE TECHNOLOGIES, INC. (US) 2015-03-17 US disclosed
US-8779008-B2 Polymeric micelles for drug delivery INTEZYNE TECHNOLOGIES, INC. (US) 2014-07-15 US disclosed
US-20130195987-A1 POLYMERIC MICELLES FOR DRUG DELIVERY INTEZYNE TECHNOLOGIES, INC. (US) 2013-08-01 US disclosed
US-8426477-B1 Polymeric micelles for drug delivery INTEZYNE TECHNOLOGIES, LLC (US) 2013-04-23 US disclosed
CN-101995771-B Coloring light-sensitive resin composition, and a colorful optical filter and a liquid crystal display device manufactured by using the coloring light-sensitive resin composition DONGWOO FINE CHEM CO LTD 2013-04-17 CN disclosed
US-8268936-B2 Synthesis of hybrid block copolymers and uses thereof INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-18 US disclosed
US-8263665-B2 Polymeric micelles for drug delivery INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-11 US disclosed
US-8263663-B2 Azide functionalized peptide targeting groups INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-11 US disclosed
US-20100136063-A1 Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides UNIVERSITY OF SOUTH FLORIDA (US) 2010-06-03 US disclosed
US-7638558-B2 drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell INTEZYNE TECHNOLOGIES, INC. (US) 2009-12-29 US disclosed
US-7618944-B2 Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks INTEZYNE TECHNOLOGIES, INC. (US) 2009-11-17 US disclosed
US-7612153-B2 conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents INTEZYNE TECHNOLOGIES, INC. (US) 2009-11-03 US disclosed
US-7601796-B2 polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions INTEZYNE TECHNOLOGIES, INC. (US) 2009-10-13 US disclosed
US-20090092554-A1 ENCAPSULATED CONTRAST AGENTS INTEZYNE TECHNOLOGIES, INC. (US) 2009-04-09 US disclosed
US-20080274173-A1 Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 US disclosed
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 US disclosed
EP-1896459-A1 NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS AstraZeneca AB (SE) 2008-03-12 EP disclosed
WO-2006137797-A1 NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS ASTRAZENECA AB (SE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136063-A1 Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides IAPP, APP, TTR IDO1 1649/4885HDAC3 4763/4885HDAC4 4159/4885
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES IAPP, APP, TTR IDO1 4405/4885HDAC3 4767/4885HDAC4 4769/4885
US-20130195987-A1 POLYMERIC MICELLES FOR DRUG DELIVERY ABCB4, CLTB, CD47 IDO1 4616/4885HDAC3 1610/4885HDAC4 2545/4885
US-20090092554-A1 ENCAPSULATED CONTRAST AGENTS LIPA, LPXN, CD47 IDO1 3635/4885HDAC3 2863/4885HDAC4 3673/4885
US-20080274173-A1 Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery CLTB, SLC1A5, CLTA IDO1 3888/4885HDAC3 3335/4885HDAC4 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.